Objective:To analyze the efficacy and safety of Agatroban in the treatment of post-circulation ischemic stroke.Methods:A total of 120 patients with posterior circulation ischemic stroke admitted to our hospital from January 2020 to December 2022 were included and divided into control group(60 cases,receiving conventional treatment)and study group(60 cases,receiving conventional treatment combined with Argatroban)by random number table method.The therapeutic effects and incidence of adverse reactions of the two groups were compared.Results:The total effective rate of the study group was higher than that of the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).After 2 weeks of treatment,compared with the control group,the National Institutes of Health Stroke Scale(NIHSS)score of the study group was significantly lower,while its baseline posterior circulation Alberta stroke project early CT score(pc-ASPECTS score)was significantly higher(P<0.05).The prothrombin time(PT)and activated partial thromboplastin time(APTT)of the study group were significantly longer(P<0.05),while its levels of serum polyamine oxidase(PAO)and S100-β protein were significantly lower(P<0.05).Conclusion:Agatroban has high efficacy and safety in the treatment of post-circulation ischemic stroke.
维普
万方数据